# PSP-Richardson 's Syndrome as a Rare Phenotypic Expression of Very Late-Onset Huntington's Disease: A Case Report

Stéphane Prange, Chloé Laurencin, Pauline Roche, Isabelle Quadrio, Stéphane Thobois

► To cite this version:

Stéphane Prange, Chloé Laurencin, Pauline Roche, Isabelle Quadrio, Stéphane Thobois. PSP-Richardson 's Syndrome as a Rare Phenotypic Expression of Very Late-Onset Huntington's Disease: A Case Report. Movement Disorders Clinical Practice, 2024, 11 (3), pp.303-305. 10.1002/mdc3.13943. hal-04801803

HAL Id: hal-04801803

https://hal.science/hal-04801803v1

Submitted on 27 Jan 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

<figure><img src="image_3.png" /></figure>

<figure><img src="image_4.png" /></figure>

# PSP-Richardson's Syndrome as a Rare Phenotypic Expression of Very Late-Onset Huntington's Disease: A Case Report

Stephane Prange, MD, PhD,<sup>1,2,3,*</sup> Chloé Laurencin, MD,<sup>1</sup> Pauline Roche, MD,<sup>1</sup> Isabelle Quadrio, MD,<sup>4</sup> and Stéphane Thobois, MD, PhD<sup>1,2,3</sup>

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disease due to increased (≥36) CAG repeats in the first exon of the huntingtin gene (HTT). HD is classically characterized by generalized chorea, and slowly progressive parkinsonism and dystonia associated with psychiatric and cognitive disorders.<fnref n="1" /> However, very unusual presentations may also exist such as the one reported here.

A 79-year-old man was first referred to our movement disorder unit for gait disorders, imbalance, and frequent falls lasting two years. He had no personal medical history and did not take any medication. Importantly, his older brother presented with mild chorea, had marked striatal atrophy on brain MRI, and was diagnosed with HD (40 ± 1 CAG repeats, with 17 repeats on the other allele) at the age of 81. The mother developed movement disorders at the age of 75 and died at 81 without genetic testing. No other of the eight siblings and their offspring had known neurological disorders. The patient had no children.

At that time, the patient had slow gait with reduced bilateral arm swing and bradykinesia, flexed posture, postural instability with frequent falls, hypomimia, slurred speech, and slowness of vertical saccades. The patient reported no recent behavioral or mood changes. Two years later, he was bedridden, with severe bilateral, akinetic-rigid parkinsonism, left hand dystonia, and dysarthria (Video 1, Segment 1). He had slow and hypometric horizontal saccades, with more severe impairment of vertical saccades and pursuit, but preserved oculocephalic reflex (Video 1, Segment 2). No chorea was observed at any time, in contrast to his older brother who had permanent chorea since the onset, which deteriorated after the withdrawal of tetrabenazine. He was demented with a dysexecutive syndrome but preserved long-term memory (MoCA 16/30; FAB 14/18). Altogether, phenotypic presentation and rapid progression

led us to diagnose progressive supranuclear palsy-Richardson's Syndrome (PSP-RS). Brain MRI was in favor, showing mesencephalic atrophy with a hummingbird sign and bilateral frontal atrophy, without marked striatal atrophy (Fig. 1A-C). Levodopa treatment up to 1000 mg daily was tried for 12 months without any success. Due to positive family history, molecular testing of HD was performed and revealed pathological HTT expansion with 40 ± 1 CAG repeats (19 repeats on the other allele).

This case illustrates a very uncommon clinical presentation corresponding to PSP-Richardson's syndrome with severe and rapidly progressive parkinsonism without chorea in a 79-year-old patient with fully penetrant, pathogenic HTT expansion (≥40 CAG repeats) and family history of very late-onset choreic HD. Thereby, this remarkable case raises several hypotheses regarding the phenotypic expression of these rare degenerative disorders in a family with late-onset HD. First, we may consider that rare atypical parkinsonism may incidentally co-occur in a patient with HD and that severe parkinsonism as observed in PSP-RS may supersede chorea, although the probability is extremely low given the low prevalence rates of both diseases.<sup>1,2</sup> Second, we cannot exclude that the patient has PSP-RS but remains presymptomatic for HD after age 80. Indeed, low-repeat HTT expansions are characterized by later onset of HD, but also greater variance (11.8 years). Overall, CAG-repeat length explains up to 65% of the variance,<sup>3,4</sup> which is further modified by the length of uninterrupted CAG repeats (not tested for our patient)<sup>3</sup> and several DNA maintenance genes.<sup>1</sup> However, the likelihood of such hypothesis remains low and CAG repeats of 40 and more are considered fully penetrant, with mean predicted motor onset at 62.6 years.<sup>5</sup>

<footnote n="1"><sup>1</sup>Hospices Civils de Lyon, Department of Neurology C, Expert Parkinson Center NS-PARK/FCRIN, Pierre Wertheimer Neurological Hospital, Bron, France; <sup>2</sup>Univ Lyon, Marc Jeannerod Cognitive Neuroscience Institute, CNRS, UMR 5229, Bron, France; <sup>3</sup>Univ Lyon, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, Université Claude Bernard Lyon 1, Oullins, France; <sup>4</sup>Hospices Civils de Lyon, Neurobiology and Neurogenetics, Department of Biochemistry and Molecular Biology, Lyon, France</footnote>

<footnote>*Correspondence to: Dr. Stephane Prange, MD, PhD, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C - Hospices Civils de Lyon 69677 Bron, France; E-mail: stephane.prange@chu-lyon.fr</footnote>

<footnote>**Keywords:** Huntington's disease, progressive supranuclear palsy, Richardson's syndrome. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. Received 31 March 2023; revised 9 October 2023; accepted 10 November 2023. Published online 3 January 2024 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mdc3.13943</footnote>
PSP-Richardson's Syndrome
as a rare phenotypic expression
of late-onset Huntington's disease

Segment 1: parkinsonism

**Video 1.** The video shows an 81-year-old man with very late-onset Huntington's disease manifesting as progressive supranuclear palsy-Richardson's syndrome, with major bradykinesia, dysarthria, amimia and supranuclear gaze palsy with preserved oculocephalic reflex. The patient is bedridden and unable to walk or stand-up.

Video content can be viewed at https://onlinelibrary.wiley.com/doi/10.1002/mdc3.13943

Third, we postulate that very late-onset HD may manifest as PSP-RS in line with recent reports. Indeed, apart from the classical choreic phenotype, HD may manifest as prominent akineto-rigid parkinsonism without chorea in young patients with large CAG expansion (Westphal variant).⁶ In addition, adult-onset HD patients with mild or no chorea but prominent parkinsonism have greater cognitive and neuropsychiatric disturbances,⁷ some with dysautonomia⁸ or oculomotor abnormalities.⁹ Notably, oculomotor abnormalities are frequent in HD, particularly for voluntary saccades, with impaired initiation including in presymptomatic patients.¹⁰ However, slowing of both horizontal and vertical saccades is more prominent in advanced HD and in patients with Westphal syndrome, pinpointing the role of brainstem pathology,¹⁰ as observed in advanced PSP-RS. Fully penetrant pathogenic HTT expansions were also demonstrated in patients with progressive supranuclear palsy/frontotemporal

dementia and amyotrophic lateral sclerosis, without chorea.²
Recently, PSP-RS phenotype was reported in a 58-year-old male patient with 41 CAG repeats and familial history of choreic HD.¹¹ Remarkably, our patient had 40 CAG repeats, as did his older brother with choreic HD of maternal inheritance, corresponding to fully penetrant alleles.

The factors which modify HD phenotype in carriers of pathogenic alleles are yet to be elucidated. Interestingly, variable phenotypic expression of HD was also observed in monozygotic twins.¹² One hypothesis is that clinical presentation might be related to regional and cell-specific CAG instability in brain structures, which may underpin the variable patterns of cortical and subcortical atrophy and be possibly favored by several genetic modifiers such as the length of uninterrupted CAG-repeats.³ Indeed, increased somatic instability in the motor and frontal cortex was observed in patients with frontotemporal dementia/amyotrophic lateral sclerosis without chorea who carried pathogenic HTT repeat expansion and had cortical huntingtin deposits, whereas no striatal degeneration was observed.² Moreover, greater somatic CAG instability in the pons, thalamus and amygdala was observed in a 73-year-old patient with PSP phenotype and pathological HTT expansion, while the caudate was less affected.¹³ Consistent with this observation, it is noteworthy that no major caudate atrophy was observed in our patient, whereas mesencephalic atrophy was prominent. Interestingly, the prevalence of patients with low penetrance alleles remains low (<0.3%) in cohorts of adults with frontotemporal dementia/amyotrophic lateral sclerosis, Lewy body dementia,² and Parkinson's disease,¹⁴ whereas intermediate (27 to 35 repeats) alleles carriers are more frequent in patients with definite MSA, some of them positive for polyglutamine staining in the pons and basal ganglia.¹⁴ Notably, polyglutamine deposits may be present in association with α-synuclein, TDP-43 or tau aggregates in patients with pathogenic HTT CAG repeats,¹,²,¹³ pinpointing the complex interaction of these protein aggregates. All these observations might be confirmed in future pathological studies.

<figure><img src="image_5.png" /></figure>

**Figure 1.** Brain MRI. Sagittal T1-weighted image (A) showing midbrain atrophy with preserved pons corresponding to the hummingbird sign. Pons to midbrain area ratio (P/M = 6.01), third ventricle to frontal horns width ratio (3rdV/FH = 0.29) and Magnetic Resonance Parkinsonism Index 2.0 (MRPI 2.0 = 3.89) index indicated prominent midbrain atrophy, as observed in PSP-RS. Axial T1-weighted images showing bilateral frontal atrophy (B) without caudate atrophy (C).
Altogether, the present case emphasizes that genetic testing of HD should be considered in patients with atypical parkinsonism, even in the absence of chorea, in case of positive family history of HD. This raises the awareness that very late-onset HD with low CAG repeats possibly manifests as atypical, non-choreic, phenotypes, which questions the role of somatic instability and differential atrophy of the striatum versus the brainstem in typical versus atypical HD.

## Author Roles

(1) Research project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the first draft, B. Review and Critique.

S.P.: 1A, 1B, 1C, 2B, 3A

C.L.: 1C; 3B

P.R.: 1C, 3B

I.Q.: 1B, 1C, 3B

S.T.: 1A, 1B, 1C, 2A, 3A

## Disclosures

**Ethical Compliance Statement:** This study was approved by the institutional Scientific and Ethics Committee (Date 21 March 2023, No. 23_103). The patient signed written informed consent regarding publishing their data and photographs. All authors confirm that they have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines.

**Funding Sources and Conflicts of Interest:** No specific funding was received for this work. The authors declare that there are no conflicts of interest relevant to this work.

**Financial Disclosures for the Previous 12 Months:** The authors declare that there are no additional disclosures to report. ■

## References

1. Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. *Nat Rev Neurol* 2020;16(10):529–546.

2. Dewan R, Chia R, Ding J, et al. Pathogenic huntingtin repeat expansions in patients with frontotemporal dementia and amyotrophic lateral sclerosis. *Neuron* 2021;109(3):448–460.e4.

3. Wright GEB, Black HF, Collins JA, Gall-Duncan T, Caron NS, Pearson CE, Hayden MR. Interrupting sequence variants and age of onset in Huntington's disease: clinical implications and emerging therapies. *Lancet Neurol* 2020;19(11):930–939.

4. Keum JW, Shin A, Gillis T, et al. The HTT CAG-expansion mutation determines age at death but not disease duration in Huntington disease. *Am J Hum Genet* 2016;98(2):287–298.

5. Langbehn DR, Hayden MR, Paulsen JS, Group and the PHI of the HS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. *Am J Med Genet B Neuropsychiatr Genet* 2010;153B(2):397–408.

6. Squitieri F, Berardelli A, Nargi E, et al. Atypical movement disorders in the early stages of Huntington's disease: clinical and genetic analysis: At onset Huntington's disease: clinical and genetic analysis. *Clin Genet* 2000; 58(1):50–56.

7. Julayanont P, Heilman KM, McFarland NR. Early-motor phenotype relates to neuropsychiatric and cognitive disorders in Huntington's disease. *Mov Disord* 2020;35(5):781–788.

8. Reuter I, Hu MT, Andrews TC, Brooks DJ, Clough C, Chaudhuri KR. Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. *J Neurol Neurosurg Psychiatry* 2000;68(2):238–241.

9. Zweig RM, Koven SJ, Hedreen JC, Maestri NE, Kazazian HH, Folstein SE. Linkage to the Huntington's disease locus in a family with unusual clinical and pathological features. *Ann Neurol* 1989;26(1):78–84.

10. Lasker AG, Zee DS. Ocular motor abnormalities in Huntington's disease. *Vision Res* 1997;37(24):3639–3645.

11. Lyons S, Lynch T, Walsh R, O'Dowd S. Mimics or multiplicity: 2 cases of rare neurological conditions discovered following presentation with Richardson's syndrome phenotype. *Mov Disord Clin Pract* 2023;10(3): 482–485.

12. Anca M h, Gazit E, Loewenthal R, Ostrovsky O, Frydman M, Giladi N. Different phenotypic expression in monozygotic twins with Huntington disease. *Am J Med Genet A* 2004;124A(1):89–91.

13. Dewan R, Jaunmuktane Z, Garcia-Segura ME, et al. CAG somatic instability in a Huntington disease expansion carrier presenting with a progressive supranuclear palsy-like phenotype. *Mov Disord* 2022;37(7): 1555–1557.

14. Pérez-Oliveira S, Álvarez I, Rosas I, et al. Intermediate and expanded HTT alleles and the risk for α-Synucleinopathies. *Mov Disord* 2022;37(9): 1841–1849.